591 results on '"Tokgözoğlu, Lale"'
Search Results
2. Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study
- Author
-
Öngen, Hürrem Gül, Akdeniz, Bahri, Düzenli, Mehmet Akif, Chernyavsky, Alexander, Dabar, Georges, Idrees, Majdy, Khludeeva, Elena, Kültürsay, Hakan, Lukianchikova, Vera, Martynyuk, Tamila, Moğulkoç, Nesrin, Mukarov, Murat A., Mutlu, Bülent, Okumuş, Gülfer, Omarov, Anuar, Önen, Zeynep Pinar, Sakkijha, Hussam, Shostak, Nadezhda, Simakova, Maria, Tokgözoğlu, Lale, Tomskaya, Tatyana, Yildirim, Hüseyin, Zateyshchikov, Dmitry, Hechenbichler, Klaus, Kessner, Stefanie, Schauerte, Isabel, Turgut, Nagihan, Vogtländer, Kai, and Aldalaan, Abdullah
- Published
- 2024
- Full Text
- View/download PDF
3. Contributors
- Author
-
Agha, Ali M., primary, Alexander, Lydia C., additional, Ballantyne, Christie M., additional, Bays, Harold, additional, Bhatt, Deepak L., additional, Blumenthal, Roger S., additional, Boffa, Michael B., additional, Bond, Rachel M., additional, Brandts, Julia M., additional, Brinton, Eliot A., additional, Brothers, Julie A., additional, Catapano, Alberico L., additional, Chan, Dick C., additional, Chiavaroli, Laura, additional, Cho, Laura Browning, additional, Cho, Leslie, additional, Cummings, Danielle, additional, Daniels, Stephen R., additional, Deshotels, Matthew R., additional, Dove, Erik, additional, Feldman, David I., additional, Fellström, Bengt, additional, Ferdinand, Keith C., additional, Fichtenbaum, Carl J., additional, Fitch, Angela, additional, Gaudet, Daniel, additional, Ginsberg, Henry N., additional, Gluckman, Ty J., additional, Hegele, Robert A., additional, Hoogeveen, Ron C., additional, Hussain, Aliza, additional, Jardine, Alan G., additional, Jenkins, David J.A., additional, Jones, Peter H., additional, Jones, Peter, additional, Kachur, Sergey M., additional, Kendall, Cyril W.C., additional, Knowles, Joshua W., additional, Kobashigawa, Jon A., additional, Koschinsky, Marlys L., additional, Kris-Etherton, Penny M., additional, Lavie, Carl J., additional, Libby, Peter, additional, Marcovina, Santica M., additional, Mark, Patrick B., additional, Marston, Nicholas A., additional, Martin, Seth Shay, additional, Michos, Erin D., additional, Mirrahimi, Arash, additional, Mora, Samia, additional, Moriarty, Patrick M., additional, Nambi, Vijay, additional, Nelson, Adam J., additional, Nicholls, Stephen J., additional, Nissen, Steven E., additional, Nordestgaard, Børge Grønne, additional, Norata, Giuseppe Danilo, additional, Orringer, Carl, additional, Palmisano, Brian T., additional, Patel, Darshna, additional, Patel, Rajan K., additional, Pulipati, Vishnu Priya, additional, Raal, Frederick J., additional, Rader, Daniel J., additional, Ray, Kausik K., additional, Richter, Chesney, additional, Ridker, Paul M., additional, Sabatine, Marc S., additional, Safarova, Maya S., additional, Santos, Raul D., additional, Saseen, Joseph J., additional, Schwartz, Gregory G., additional, Shustak, Rachel J., additional, Sievenpiper, John L., additional, Singh, Nickpreet, additional, Skulas-Ray, Ann C., additional, Srichaikul, Kristie, additional, Stone, Neil J., additional, Tokgözoğlu, Lale, additional, Tybjærg-Hansen, Anne, additional, Virani, Salim S., additional, Watson, Karol, additional, Watts, Gerald F., additional, Wenger, Nanette K., additional, and Wong, Julia M.W., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Statins
- Author
-
Tokgözoğlu, Lale, primary, Orringer,, Carl, additional, and Saseen, Joseph J., additional
- Published
- 2024
- Full Text
- View/download PDF
5. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
- Author
-
Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed, Cherney, David Z.I., DeFronzo, Ralph A., Del Prato, Stefano, Eckel, Robert H., Filippatos, Gerasimos, Fonarow, Gregg C., Fonseca, Vivian A., Garvey, W. Timothy, Giorgino, Francesco, Grant, Peter J., Green, Jennifer B., Greene, Stephen J., Groop, Per-Henrik, Grunberger, George, Jastreboff, Ania M., Jellinger, Paul S., Khunti, Kamlesh, Klein, Samuel, Kosiborod, Mikhail N., Kushner, Pamela, Leiter, Lawrence A., Lepor, Norman E., Mantzoros, Christos S., Mathieu, Chantal, Mende, Christian W., Michos, Erin D., Morales, Javier, Plutzky, Jorge, Pratley, Richard E., Ray, Kausik K., Rossing, Peter, Sattar, Naveed, Schwarz, Peter E.H., Standl, Eberhard, Steg, P. Gabriel, Tokgözoğlu, Lale, Tuomilehto, Jaakko, Umpierrez, Guillermo E., Valensi, Paul, Weir, Matthew R., Wilding, John, and Wright, Eugene E., Jr.
- Published
- 2024
- Full Text
- View/download PDF
6. Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
- Author
-
Şener, Yusuf Ziya and Tokgözoğlu, Lale
- Published
- 2023
- Full Text
- View/download PDF
7. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook
- Author
-
Raja, Vikrama, Aguiar, Carlos, Alsayed, Nasreen, Chibber, Yogeyaa S., ElBadawi, Hussein, Ezhov, Marat, Hermans, Michel P., Pandey, Ramesh Chandra, Ray, Kausik K., Tokgözoglu, Lale, Zambon, Alberto, Berrou, Jean-Pascal, and Farnier, Michel
- Published
- 2023
- Full Text
- View/download PDF
8. Meta-analysis of the Current Research on the Relationship Between Blood Lipid Levels and the Occurrence of Atrial Fibrillation
- Author
-
Hayıroğlu, Mert İlker, Şaylık, Faysal, Çınar, Tufan, and Tokgözoğlu, Lale
- Published
- 2023
- Full Text
- View/download PDF
9. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
- Author
-
Kronenberg, Florian, Mora, Samia, Stroes, Erik S.G., Ference, Brian A., Arsenault, Benoit J., Berglund, Lars, Dweck, Marc R., Koschinsky, Marlys L., Lambert, Gilles, Mach, François, McNeal, Catherine J., Moriarty, Patrick M., Natarajan, Pradeep, Nordestgaard, Børge G., Parhofer, Klaus G., Virani, Salim S., von Eckardstein, Arnold, Watts, Gerald F., Stock, Jane K., Ray, Kausik K., Tokgözoğlu, Lale S., and Catapano, Alberico L.
- Published
- 2023
- Full Text
- View/download PDF
10. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network
- Author
-
Catapano, Alberico L., Tokgözoğlu, Lale, Banach, Maciej, Gazzotti, Marta, Olmastroni, Elena, Casula, Manuela, and Ray, Kausik K.
- Published
- 2023
- Full Text
- View/download PDF
11. Chasing LDL cholesterol to the bottom — PCSK9 in perspective
- Author
-
Libby, Peter and Tokgözoğlu, Lale
- Published
- 2022
- Full Text
- View/download PDF
12. Baseline Characteristics and Clinical Insights from the ARTEMIS Registry: A Comprehensive Study of Peripartum Cardiomyopathy in Türkiye.
- Author
-
Kayıkçıoğlu, Meral, Biteker, Murat, Mutluer, Ferit Onur, Güzel, Tuncay, Yılmaz, Emre, Demir, Emre, Nalbantgil, Sanem, Ertaş, Faruk, Yılmaz, Dilek Çiçek, Temizhan, Ahmet, Aşkın, Lütfü, Asarcıklı, Lale Dinç, Akçay, Murat, Demirbağ, Recep, Köroğlu, Sedat, Örnek, Ender, Çelik, Ahmet, Akıl, Mehmet Ata, Arslan, Bayram, and Tokgözoğlu, Lale
- Abstract
Copyright of Archives of the Turkish Society of Cardiology / Türk Kardiyoloji Derneği Arşivi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
13. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
- Author
-
Mach, François, Ray, Kausik K, Wiklund, Olov, Corsini, Alberto, Catapano, Alberico L, Bruckert, Eric, De Backer, Guy, Hegele, Robert A, Hovingh, G Kees, Jacobson, Terry A, Krauss, Ronald M, Laufs, Ulrich, Leiter, Lawrence A, März, Winfried, Nordestgaard, Børge G, Raal, Frederick J, Roden, Michael, Santos, Raul D, Stein, Evan A, Stroes, Erik S, Thompson, Paul D, Tokgözoğlu, Lale, Vladutiu, Georgirene D, Gencer, Baris, Stock, Jane K, Ginsberg, Henry N, and Chapman, M John
- Subjects
Aging ,Brain Disorders ,Prevention ,Patient Safety ,Liver Disease ,Clinical Trials and Supportive Activities ,Digestive Diseases ,Stroke ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,Aetiology ,2.1 Biological and endogenous factors ,6.1 Pharmaceuticals ,Cataract ,Cerebral Hemorrhage ,Chemical and Drug Induced Liver Injury ,Cognition Disorders ,Glucose ,Homeostasis ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Kidney Diseases ,European Atherosclerosis Society Consensus Panel ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Cardiovascular System & Hematology - Abstract
AimsTo objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract.Methods and resultsA literature search covering 2000-2017 was performed. The Panel critically appraised the data and agreed by consensus on the categorization of reported adverse effects. Randomized controlled trials (RCTs) and genetic studies show that statin therapy is associated with a modest increase in the risk of new-onset diabetes mellitus (about one per thousand patient-years), generally defined by laboratory findings (glycated haemoglobin ≥6.5); this risk is significantly higher in the metabolic syndrome or prediabetes. Statin treatment does not adversely affect cognitive function, even at very low levels of low-density lipoprotein cholesterol and is not associated with clinically significant deterioration of renal function, or development of cataract. Transient increases in liver enzymes occur in 0.5-2% of patients taking statins but are not clinically relevant; idiosyncratic liver injury due to statins is very rare and causality difficult to prove. The evidence base does not support an increased risk of haemorrhagic stroke in individuals without cerebrovascular disease; a small increase in risk was suggested by the Stroke Prevention by Aggressive Reduction of Cholesterol Levels study in subjects with prior stroke but has not been confirmed in the substantive evidence base of RCTs, cohort studies and case-control studies.ConclusionLong-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.
- Published
- 2018
14. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement
- Author
-
Belch, Jill J.F., Brodmann, Marianne, Baumgartner, Iris, Binder, Christoph J., Casula, Manuela, Heiss, Christian, Kahan, Thomas, Parini, Paolo, Poredos, Pavel, Catapano, Alberico L., and Tokgözoğlu, Lale
- Published
- 2021
- Full Text
- View/download PDF
15. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- Author
-
Ference, Brian A, Ginsberg, Henry N, Graham, Ian, Ray, Kausik K, Packard, Chris J, Bruckert, Eric, Hegele, Robert A, Krauss, Ronald M, Raal, Frederick J, Schunkert, Heribert, Watts, Gerald F, Borén, Jan, Fazio, Sergio, Horton, Jay D, Masana, Luis, Nicholls, Stephen J, Nordestgaard, Børge G, van de Sluis, Bart, Taskinen, Marja-Riitta, Tokgözoğlu, Lale, Landmesser, Ulf, Laufs, Ulrich, Wiklund, Olov, Stock, Jane K, Chapman, M John, and Catapano, Alberico L
- Subjects
Cardiovascular ,Atherosclerosis ,Clinical Trials and Supportive Activities ,Clinical Research ,2.1 Biological and endogenous factors ,Aetiology ,Anticholesteremic Agents ,Cholesterol ,HDL ,Cholesterol ,LDL ,Consensus ,Epidemiologic Methods ,Ezetimibe ,Genetic Predisposition to Disease ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Hyperlipidemias ,Lipoproteins ,LDL ,PCSK9 Inhibitors ,Cardiovascular disease ,Causality ,Clinical trials ,Low-density lipoprotein ,Mendelian randomization ,PCSK9 ,Recommendations ,Statin ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Cardiovascular System & Hematology - Abstract
AimsTo appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD).Methods and resultsWe assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects.ConclusionConsistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
- Published
- 2017
16. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
- Author
-
Atar, Dan, Jukema, J. Wouter, Molemans, Bart, Taub, Pam R., Goto, Shinya, Mach, François, CerezoOlmos, Cesar, Underberg, James, Keech, Anthony, Tokgözoğlu, Lale, and Bonaca, Marc P.
- Published
- 2021
- Full Text
- View/download PDF
17. Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry)
- Author
-
Kuman Tunçel, Özlem, Kayıkçıoğlu, Meral, Pırıldar, Şebnem, Yılmaz, Mehmet, Kaynar, Leylagül, Aktan, Melih, Durmuş, Rana Berru, Gökçe, Cumali, Temizhan, Ahmet, Özcebe, Osman İlhami, Karaağaç Akyol, Tülay, Okutan, Harika, Sağ, Saim, Öz Gül, Özen, Yenerçağ, Mustafa, Altunkeser, Bülent Behlül, Kuku, İrfan, Yılmaz Yaşar, Hamiyet, Kurtoğlu, Erdal, Demircioğlu, Sinan, Pekkolay, Zafer, İlhan, Osman, and Tokgözoğlu, Lale
- Published
- 2020
- Full Text
- View/download PDF
18. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement
- Author
-
Hegele, Robert A, Borén, Jan, Ginsberg, Henry N, Arca, Marcello, Averna, Maurizio, Binder, Christoph J, Calabresi, Laura, Chapman, M John, Cuchel, Marina, von Eckardstein, Arnold, Frikke-Schmidt, Ruth, Gaudet, Daniel, Hovingh, G Kees, Kronenberg, Florian, Lütjohann, Dieter, Parhofer, Klaus G, Raal, Frederick J, Ray, Kausik K, Remaley, Alan T, Stock, Jane K, Stroes, Erik S, Tokgözoğlu, Lale, and Catapano, Alberico L
- Published
- 2020
- Full Text
- View/download PDF
19. Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study
- Author
-
Çavuşoğlu, Yüksel, primary, Başarıcı, İbrahim, additional, Tüfekçioğlu, Omaç, additional, Özpelit, Ebru, additional, Özdemir, Elif, additional, Sivrikoz, İlknur Ak, additional, Altay, Hakan, additional, Değertekin, Muzaffer, additional, Dinçer, İrem, additional, İkitimur, Barış, additional, Kahveci, Gökhan, additional, Bozkurt, Murat Fani, additional, Erkılıç, Metin, additional, Kaya, Gamze Çapa, additional, Beksaç, Meral, additional, Salihoğlu, Ayşe, additional, and Tokgözoğlu, Lale, additional
- Published
- 2024
- Full Text
- View/download PDF
20. World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
- Author
-
Laranjo, Liliana, primary, Lanas, Fernando, additional, Sun, Marie Chan, additional, Chen, Deborah Anne, additional, Hynes, Lisa, additional, Imran, Tasnim F., additional, Kazi, Dhruv S., additional, Kengne, Andre Pascal, additional, Komiyama, Maki, additional, Kuwabara, Masanari, additional, Lim, Jeremy, additional, Perel, Pablo, additional, Piñeiro, Daniel José, additional, Ponte-Negretti, Carlos I., additional, Séverin, Tania, additional, Thompson, David R., additional, Tokgözoğlu, Lale, additional, Yan, Lijing L., additional, and Chow, Clara K., additional
- Published
- 2024
- Full Text
- View/download PDF
21. Incidence of cardiovascular events in patients with stabilized coronary heart disease : the EUROASPIRE IV follow-up study
- Author
-
De Bacquer, Dirk, De Smedt, Delphine, Kotseva, Kornelia, Jennings, Catriona, Wood, David, Rydén, Lars, Gyberg, Viveca, Shahim, Bahira, Amouyel, Philippe, Bruthans, Jan, Conde, Almudena Castro, Cífková, Renata, Deckers, Jaap W., De Sutter, Johan, Dilic, Mirza, Dolzhenko, Maryna, Erglis, Andrejs, Fras, Zlatko, Gaita, Dan, Gotcheva, Nina, Goudevenos, John, Heuschmann, Peter, Laucevicius, Aleksandras, Lehto, Seppo, Lovic, Dragan, Miličić, Davor, Moore, David, Nicolaides, Evagoras, Oganov, Raphael, Pajak, Andrzej, Pogosova, Nana, Reiner, Zeljko, Stagmo, Martin, Störk, Stefan, Tokgözoğlu, Lale, Vulic, Dusko, Wagner, Martin, and De Backer, Guy
- Published
- 2019
22. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
- Author
-
Stroes, Erik S, Thompson, Paul D, Corsini, Alberto, Vladutiu, Georgirene D, Raal, Frederick J, Ray, Kausik K, Roden, Michael, Stein, Evan, Tokgözoğlu, Lale, Nordestgaard, Børge G, Bruckert, Eric, De Backer, Guy, Krauss, Ronald M, Laufs, Ulrich, Santos, Raul D, Hegele, Robert A, Hovingh, G Kees, Leiter, Lawrence A, Mach, Francois, März, Winfried, Newman, Connie B, Wiklund, Olov, Jacobson, Terry A, Catapano, Alberico L, Chapman, M John, Ginsberg, Henry N, Stroes, Erik, John Chapman, M, de Backer, Guy, Kees Hovingh, G, and Leiter, Lawrence
- Subjects
Clinical Research ,Cardiovascular ,Atherosclerosis ,2.1 Biological and endogenous factors ,Aetiology ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Cholesterol Ester Transfer Proteins ,Complementary Therapies ,Consensus ,Creatine Kinase ,Diet ,Genetic Predisposition to Disease ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Hypolipidemic Agents ,Mitochondria ,Muscle ,Mitochondrial Diseases ,Muscular Diseases ,Proprotein Convertase 9 ,Proprotein Convertases ,Risk Factors ,Serine Endopeptidases ,European Atherosclerosis Society Consensus Panel ,Cholesterol ,Consensus statement ,Lipids ,Mitochondrial ,Muscle symptoms ,Myalgia ,Myopathy ,Statin ,Statin intolerance ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Cardiovascular System & Hematology - Abstract
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.
- Published
- 2015
23. PCSK9 inhibition and inflammation: A narrative review
- Author
-
Ruscica, Massimiliano, Tokgözoğlu, Lale, Corsini, Alberto, and Sirtori, Cesare R.
- Published
- 2019
- Full Text
- View/download PDF
24. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
- Author
-
Fruchart, Jean-Charles, Santos, Raul D., Yamashita, Shizuya, Aikawa, Masanori, Libby, Peter, Plutzky, Jorge, Pradhan, Aruna, Ridker, Paul, Aguilar-Salinas, Carlos, Al Rasadi, Khalid, Amarenco, Pierre, Barter, Philip J., Ceska, Richard, Corsini, Alberto, Ruscica, Massimiliano, Després, Jean-Pierre, Duriez, Patrick, Eckel, Robert H., Ezhov, Marat V., Farnier, Michel, Ginsberg, Henry N., Hermans, Michel P., Ishibashi, Shun, Karpe, Fredrik, Kodama, Tatsuhiko, Koenig, Wolfgang, Krempf, Michel, Lim, Soo, Lorenzatti, Alberto J., McPherson, Ruth, Nuñez-Cortes, Jesus Millan, Nordestgaard, Børge G., Ogawa, Hisao, Packard, Chris J., Ponte-Negretti, Carlos I., Reiner, Željko, Sadikot, Shaukat, Shimano, Hitoshi, Sritara, Piyamitr, Stock, Jane K., Su, Ta-Chen, Susekov, Andrey V., Tartar, André, Taskinen, Marja-Riitta, Tenenbaum, Alexander, Tokgözoğlu, Lale S., Tomlinson, Brian, Tybjærg-Hansen, Anne, Valensi, Paul, Vrablík, Michal, Wahli, Walter, Watts, Gerald F., Yokote, Koutaro, and Zambon, Alberto
- Published
- 2019
- Full Text
- View/download PDF
25. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
- Author
-
De Backer, G., Jankowski, P., Kotseva, K., Mirrakhimov, E., Reiner, Z., Rydén, L., Tokgözoğlu, L., Wood, D., De Bacquer, D., Abreu, A., Aguiar, C., Badariene, J., Bruthans, J., Castro Conde, A., Cifkova, R., Crowley, J., Davletov, K., Bacquer, D. De, De Smedt, D., De Sutter, J., Deckers, J.W., Dilic, M., Dolzhenko, M., Druais, H., Dzerve, V., Erglis, A., Fras, Z., Gaita, D., Gotcheva, N., Grobbee, D.E., Gyberg, V., Hasan Ali, H., Heuschmann, P., Hoes, A.W., Lalic, N., Lehto, S., Lovic, D., Maggioni, A.P., Mancas, S., Marques-Vidal, P., Mellbin, L., Miličić, D., Oganov, R., Pogosova, N., Reiner, Ž., Stagmo, M., Störk, S., Sundvall, J., Tsioufis, K., Vulic, D., Wood, D.A., Jennings, C., Adamska, A., Adamska, S., Tuomilehto, J., Schnell, O., Fiorucci, E., Glemot, M., Larras, F., Missiamenou, V., Maggioni, A., Taylor, C., Ferreira, T., Lemaitre, K., Raman, L., DeSmedt, D., Willems, A.M., De Pauw, M., Vervaet, P., Bollen, J., Dekimpe, E., Mommen, N., Van Genechten, G., Dendale, P., Bouvier, C.A., Chenu, P., Huyberechts, D., Persu, A., Begic, A., Durak Nalbantic, A., Dzubur, A., Hadzibegic, N., Iglica, A., Kapidjic, S., Osmanagic Bico, A., Resic, N., Sabanovic Bajramovic, N., Zvizdic, F., Kovacevic-Preradovic, T., Popovic-Pejicic, S., Djekic, D., Gnjatic, T., Knezevic, T., Kos, Lj, Stanetic, B., Topic, G., Georgiev, Borislav, Terziev, A., Vladimirov, G., Angelov, A., Kanazirev, B., Nikolaeva, S., Tonkova, D., Vetkova, M., Milicic, D., Bosnic, A., Dubravcic, M., Glavina, M., Mance, M., Pavasovic, S., Samardzic, J., Batinic, T., Crljenko, K., Delic-Brkljacic, D., Dula, K., Golubic, K., Klobucar, I., Kordic, K., Kos, N., Nedic, M., Olujic, D., Sedinic, V., Blazevic, T., Pasalic, A., Percic, M., Sikic, J., Cífková, R., Hašplová, K., Šulc, P., Wohlfahrt, P., Mayer, O., Jr., Cvíčela, M., Filipovský, J., Gelžinský, J., Hronová, M., Hasan-Ali, H., Bakery, S., Mosad, E., Hamed, H.B., Ibrahim, A., Elsharef, M.A., Kholef, E.F., Shehata, A., Youssef, M., Elhefny, E., Farid, H., Moustafa, T.M., Sobieh, M.S., Kabil, H., Abdelmordy, A., Kiljander, E., Kiljander, P., Koukkunen, H., Mustonen, J., Cremer, C., Frantz, S., Haupt, A., Hofmann, U., Ludwig, K., Melnyk, H., Noutsias, M., Karmann, W., Prondzinsky, R., Herdeg, C., Hövelborn, T., Daaboul, A., Geisler, T., Keller, T., Sauerbrunn, D., Walz-Ayed, M., Ertl, G., Leyh, R., Ehlert, T., Klocke, B., Krapp, J., Ludwig, T., Käs, J., Starke, C., Ungethüm, K., Wagner, M., Wiedmann, S., Tolis, P., Vogiatzi, G., Sanidas, E., Tsakalis, K., Kanakakis, J., Koutsoukis, A., Vasileiadis, K., Zarifis, J., Karvounis, C., Gibson, I., Houlihan, A., Kelly, C., O'Donnell, M., Bennati, M., Cosmi, F., Mariottoni, B., Morganti, M., Cherubini, A., Di Lenarda, A., Radini, D., Ramani, F., Francese, M.G., Gulizia, M.M., Pericone, D., Aigerim, K., Zholdin, B., Amirov, B., Assembekov, B., Chernokurova, E., Ibragimova, F., Kodasbayev, A., Markova, A., Asanbaev, A., Toktomamatov, U., Tursunbaev, M., Zakirov, U., Abilova, S., Arapova, R., Bektasheva, E., Esenbekova, J., Neronova, K., Baigaziev, K., Baitova, G., Zheenbekov, T., Andrejeva, T., Bajare, I., Kucika, G., Labuce, A., Putane, L., Stabulniece, M., Klavins, E., Sime, I., Gedvilaite, L., Pečiuraite, D., Sileikienė, V., Skiauteryte, E., Solovjova, S., Sidabraite, R., Briedis, K., Ceponiene, I., Jurenas, M., Kersulis, J., Martinkute, G., Vaitiekiene, A., Vasiljevaite, K., Veisaite, R., Plisienė, J., Šiurkaitė, V., Vaičiulis, Ž., Czarnecka, D., Kozieł, P., Podolec, P., Nessler, J., Gomuła, P., Mirek-Bryniarska, E., Bogacki, P., Wiśniewski, A., Pająk, A., Wolfshaut-Wolak, R., Bućko, J., Kamiński, K., Łapińska, M., Paniczko, M., Raczkowski, A., Sawicka, E., Stachurska, Z., Szpakowicz, M., Musiał, W., Dobrzycki, S., Bychowski, J., Kosior, D.A., Krzykwa, A., Setny, M., Rak, A., Gąsior, Z., Haberka, M., Szostak-Janiak, K., Finik, M., Liszka, J., Botelho, A., Cachulo, M., Sousa, J., Pais, A., Durazzo, A., Matos, D., Gouveia, R., Rodrigues, G., Strong, C., Guerreiro, R., Aguiar, J., Cruz, M., Daniel, P., Morais, L., Moreira, R., Rosa, S., Rodrigues, I., Selas, M., Apostu, A., Cosor, O., Gaita, L., Giurgiu, L., Hudrea, C., Maximov, D., Moldovan, B., Mosteoru, S., Pleava, R., Ionescu, M., Parepa, I., Arutyunov, A., Ausheva, A., Isakova, S., Karpova, A., Salbieva, A., Sokolova, O., Vasilevsky, A., Pozdnyakov, Y., Antropova, O., Borisova, L., Osipova, I., Aleksic, M., Crnokrak, B., Djokic, J., Hinic, S., Vukasin, T., Zdravkovic, M., Lalic, N.M., Jotic, A., Lalic, K., Lukic, L., Milicic, T., Macesic, M., Stanarcic Gajovic, J., Stoiljkovic, M., Djordjevic, D., Kostic, S., Tasic, I., Vukovic, A., Jug, B., Juhant, A., Krt, A., Kugonjič, U., Chipayo Gonzales, D., Gómez Barrado, J.J., Kounka, Z., Marcos Gómez, G., Mogollón Jiménez, M.V., Ortiz Cortés, C., Perez Espejo, P., Porras Ramos, Y., Colman, R., Delgado, J., Otero, E., Pérez, A., Fernández-Olmo, M.R., Torres-LLergo, J., Vasco, C., Barreñada, E., Botas, J., Campuzano, R., González, Y., Rodrigo, M., de Pablo, C., Velasco, E., Hernández, S., Lozano, C., González, P., Castro, A., Dalmau, R., Hernández, D., Irazusta, F.J., Vélez, A., Vindel, C., Gómez-Doblas, J.J., García Ruíz, V., Gómez, L., Gómez García, M, Jiménez-Navarro, M., Molina Ramos, A., Marzal, D., Martínez, G., Lavado, R., Vidal, A., Boström-Nilsson, V., Kjellström, B., Shahim, B., Smetana, S., Hansen, O., Stensgaard-Nake, E., Klijn, A.J., Mangus, T.J.P., Peters, R.J.G., Scholte op Reimer, W., Snaterse, M., Aydoğdu, S., Ç Erol, Otürk, S., Tulunay Kaya, C., Ahmetoğlu, Y., Ergene, O., Akdeniz, B., Çırgamış, D., Akkoyun H Kültürsay, S., Kayıkçıoğlu, M., Çatakoğlu, A.B., Çengel, A., Koçak, A.A., Ağırbaşlı, M.A., Açıksarı, G., Çekin, M.E., Kaya, E.B., Koçyiğit, D., Öngen, Z., Özmen, E., Sansoy, V., Kaya, A., Oktay, V., Temizhan, A., Ünal, S., İ Yakut, Kalkan, A.K., Bozkurt, E., Kasapkara, H.A., Faradzh, C., Hrubyak, L., Konoplianyk, L., Kozhuharyova, N., Lobach, L., Nesukai, V., Nudchenko, O., Simagina, T., Yakovenko, L., Azarenko, V., Potabashny, V., Bazylevych, A., Bazylevych, M., Kaminska, K., Panchenko, L., Shershnyova, O., Ovrakh, T., Serik, S., Kolesnik, T., Kosova, H., Hoye P Atkin, A., Fellowes, D., Lindsay, S., Atkinson, C., Kranilla, C., Vinod, M., Beerachee, Y., Bennett, C., Broome, M., Bwalya, A., Caygill, Lindsay, Dinning, L., Gillespie, A., Goodfellow, R., Guy, J., Idress, T., Mills, C., Morgan, C., Oustance, N., Singh, N., Yare, M., Jagoda, J.M., Bowyer, H., Christenssen, V., Groves, A., Jan, A., Riaz, A., Gill, M., Sewell, T.A., Gorog, D., Baker, M., De Sousa, P., Mazenenga, T., Porter, J., Haines, F., Peachey, T., Taaffe, J., Wells, K., Ripley, D.P., Forward, H., McKie, H., Pick, S.L., Thomas, H.E., Batin, P.D., Exley, D., Rank, T., Wright, J., Kardos, A., Sutherland, S.-B., Wren, L., Leeson, P., Barker, D., Moreby, B., Sawyer, J., Stirrup, J., Brunton, M., Brodison, A., Craig, J., Peters, S., Kaprielian, R., Bucaj, A., Mahay, K., Oblak, M., Gale, C., Pye, M., McGill, Y., Redfearn, H., Fearnley, M., De Backer, Guy, Jankowski, Piotr, Kotseva, Kornelia, Mirrakhimov, Erkin, Reiner, Željko, Rydén, Lars, Tokgözoğlu, Lale, Wood, David, and De Bacquer, Dirk
- Published
- 2019
- Full Text
- View/download PDF
26. Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering
- Author
-
Norata, Giuseppe Danilo, primary and Tokgözoğlu, Lale, additional
- Published
- 2023
- Full Text
- View/download PDF
27. Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials
- Author
-
Tokgözoğlu, Lale, primary, Pirillo, Angela, additional, and Catapano, Alberico Luigi, additional
- Published
- 2023
- Full Text
- View/download PDF
28. Influence of sex and gender on the biology of atherosclerotic cardiovascular disease: Special issue
- Author
-
Osto, Elena, primary, Roeters van Lennep, Jeanine E., additional, Tokgözoğlu, Lale, additional, and Öörni, Katariina, additional
- Published
- 2023
- Full Text
- View/download PDF
29. The prevalence and impact of renal artery stenosis in patients undergoing TAVI
- Author
-
Şener, Yusuf Ziya, Yetkin, Ahmet, Düzgün, Selin Ardali, Ateş, Ahmet Hakan, Şahiner, Mehmet Levent, Kaya, Ergün Barış, Hazirolan, Tuncay, Aytemir, Kudret, and Tokgözoğlu, Lale
- Published
- 2024
- Full Text
- View/download PDF
30. Efficacy and safety of alirocumab in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke: Data mining of phase 3 odyssey studies
- Author
-
Filardi, Pasqual Perrone, Tokgözoğlu, Lale, Cabezas, Manuel Castro, Marx, Nikolaus, Tuñón, José, Pereira, Carla, and Bhatt, Deepak
- Published
- 2024
- Full Text
- View/download PDF
31. Association between atherogenic index of plasma and both coronary and breast artery calcification
- Author
-
Şener, Yusuf Ziya, Okşul, Metin, Yildirim, Arzu, Sarikaya, Yasin, Arslan, Sevtap, Düzgün, Selin Ardali, Akpinar, Meltem Gülsün, Hazirolan, Tuncay, and Tokgözoğlu, Lale
- Published
- 2024
- Full Text
- View/download PDF
32. Turk-heart: A study designed to determine strategies for achieving recommended dyslipidemia treatment goals in very high CVD risk patients in Turkey
- Author
-
Ozdogan, Oner, Basaran, Ozcan, Gungor, Baris, Kayikcioglu, Meral, Ozkan, Bugra, Kus, Mesut, and Tokgözoğlu, Lale
- Published
- 2024
- Full Text
- View/download PDF
33. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
- Author
-
Vallejo-Vaz, Antonio J., De Marco, Martina, Stevens, Christophe A.T., Akram, Asif, Freiberger, Tomas, Hovingh, G. Kees, Kastelein, John J.P., Mata, Pedro, Raal, Frederick J., Santos, Raul D., Soran, Handrean, Watts, Gerald F., Abifadel, Marianne, Aguilar-Salinas, Carlos A., Al-khnifsawi, Mutaz, AlKindi, Fahad A., Alnouri, Fahad, Alonso, Rodrigo, Al-Rasadi, Khalid, Al-Sarraf, Ahmad, Ashavaid, Tester F., Binder, Christoph J., Bogsrud, Martin P., Bourbon, Mafalda, Bruckert, Eric, Chlebus, Krzysztof, Corral, Pablo, Descamps, Olivier, Durst, Ronen, Ezhov, Marat, Fras, Zlatko, Genest, Jacques, Groselj, Urh, Harada-Shiba, Mariko, Kayikcioglu, Meral, Lalic, Katarina, Lam, Carolyn S.P., Latkovskis, Gustavs, Laufs, Ulrich, Liberopoulos, Evangelos, Lin, Jie, Maher, Vincent, Majano, Nelson, Marais, A. David, März, Winfried, Mirrakhimov, Erkin, Miserez, André R., Mitchenko, Olena, Nawawi, Hapizah M., Nordestgaard, Børge G., Paragh, György, Petrulioniene, Zaneta, Pojskic, Belma, Postadzhiyan, Arman, Reda, Ashraf, Reiner, Željko, Sadoh, Wilson E., Sahebkar, Amirhossein, Shehab, Abdullah, Shek, Aleksander B., Stoll, Mario, Su, Ta-Chen, Subramaniam, Tavintharan, Susekov, Andrey V., Symeonides, Phivos, Tilney, Myra, Tomlinson, Brian, Truong, Thanh-Huong, Tselepis, Alexandros D., Tybjærg-Hansen, Anne, Vázquez-Cárdenas, Alejandra, Viigimaa, Margus, Vohnout, Branislav, Widén, Elisabeth, Yamashita, Shizuya, Banach, Maciej, Gaita, Dan, Jiang, Lixin, Nilsson, Lennart, Santos, Lourdes E., Schunkert, Heribert, Tokgözoğlu, Lale, Car, Josip, Catapano, Alberico L., and Ray, Kausik K.
- Published
- 2018
- Full Text
- View/download PDF
34. Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials.
- Author
-
Tokgözoğlu, Lale, Pirillo, Angela, and Catapano, Alberico Luigi
- Subjects
DYSLIPIDEMIA ,LIPOPROTEIN lipase ,CHOLESTERYL ester transfer protein ,APOLIPOPROTEIN C ,MAJOR adverse cardiovascular events ,CORONARY artery calcification - Abstract
The article discusses the relationship between triglyceride (TG) levels and cardiovascular disease (CVD) risk. While controlling elevated levels of low-density lipoprotein-cholesterol (LDL-C) is a common approach to preventing CVD, studies suggest that elevated TG levels are an independent risk factor for atherosclerotic CVD. However, previous clinical trials targeting TG reduction have not provided conclusive evidence of its impact on CVD risk. The article highlights the importance of measuring apolipoprotein B (apoB) levels, which can accurately assess the number of atherogenic lipoproteins, and suggests that reducing apoB-containing lipoproteins may be more effective in reducing CVD risk than solely reducing TG levels. The article also discusses the findings of recent trials on TG-lowering agents and their impact on CVD risk. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
35. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
- Author
-
Roeters van Lennep, Jeanine E, primary, Tokgözoğlu, Lale S, additional, Badimon, Lina, additional, Dumanski, Sandra M, additional, Gulati, Martha, additional, Hess, Connie N, additional, Holven, Kirsten B, additional, Kavousi, Maryam, additional, Kayıkçıoğlu, Meral, additional, Lutgens, Esther, additional, Michos, Erin D, additional, Prescott, Eva, additional, Stock, Jane K, additional, Tybjaerg-Hansen, Anne, additional, Wermer, Marieke J H, additional, and Benn, Marianne, additional
- Published
- 2023
- Full Text
- View/download PDF
36. Glycerol and β-hydroxybutyrate: friends or foes?
- Author
-
Tokgözoğlu, Lale, primary, Pirillo, Angela, additional, and Catapano, Alberico Luigi, additional
- Published
- 2023
- Full Text
- View/download PDF
37. A Woman’s Heart: Improving Uptake and Awareness of Cardiovascular Screening for Middle-Aged Populations
- Author
-
Kazzi, Brigitte, primary, Shankar, Bairavi, additional, Elder-Odame, Petal, additional, Tokgözoğlu, Lale S, additional, Sierra-Galan, Lilia M, additional, and Michos, Erin D, additional
- Published
- 2023
- Full Text
- View/download PDF
38. 17 - Statins
- Author
-
Tokgözoğlu, Lale, Orringer, Carl, and Saseen, Joseph J.
- Published
- 2024
- Full Text
- View/download PDF
39. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
- Author
-
Kronenberg, Florian, Mora, Samia, Stroes, Erik S G, Ference, Brian A, Arsenault, Benoit J, Berglund, Lars, Dweck, Marc R, Koschinsky, Marlys, Lambert, Gilles, Mach, François, McNeal, Catherine J, Moriarty, Patrick M, Natarajan, Pradeep, Nordestgaard, Børge G, Parhofer, Klaus G, Virani, Salim S, von Eckardstein, Arnold, Watts, Gerald F, Stock, Jane K, Ray, Kausik K, Tokgözoğlu, Lale S, Catapano, Alberico L, University of Zurich, Experimental Vascular Medicine, Vascular Medicine, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Adult ,Consensus ,Aortic stenosis ,Testing ,Calcinosis ,610 Medicine & health ,Aortic Valve Stenosis ,Cholesterol, LDL ,Cardiovascular risk ,Atherosclerosis ,2705 Cardiology and Cardiovascular Medicine ,Model of care ,Treatment ,Cardiovascular Diseases ,Risk Factors ,Clinical guidance ,540 Chemistry ,Humans ,Cardiology and Cardiovascular Medicine ,10038 Institute of Clinical Chemistry ,Lipoprotein(a) - Abstract
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treating elevated Lp(a) levels, and considers its inclusion in global risk estimation. Epidemiologic and genetic studies involving hundreds of thousands of individuals strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes in different ethnicities; elevated Lp(a) is a risk factor even at very low levels of low-density lipoprotein cholesterol. High Lp(a) is associated with both microcalcification and macrocalcification of the aortic valve. Current findings do not support Lp(a) as a risk factor for venous thrombotic events and impaired fibrinolysis. Very low Lp(a) levels may associate with increased risk of diabetes mellitus meriting further study. Lp(a) has pro-inflammatory and pro-atherosclerotic properties, which may partly relate to the oxidized phospholipids carried by Lp(a). This panel recommends testing Lp(a) concentration at least once in adults; cascade testing has potential value in familial hypercholesterolaemia, or with family or personal history of (very) high Lp(a) or premature ASCVD. Without specific Lp(a)-lowering therapies, early intensive risk factor management is recommended, targeted according to global cardiovascular risk and Lp(a) level. Lipoprotein apheresis is an option for very high Lp(a) with progressive cardiovascular disease despite optimal management of risk factors. In conclusion, this statement reinforces evidence for Lp(a) as a causal risk factor for cardiovascular outcomes. Trials of specific Lp(a)-lowering treatments are critical to confirm clinical benefit for cardiovascular disease and aortic valve stenosis.
- Published
- 2022
40. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
- Author
-
Cuchel, Marina, primary, Raal, Frederick J, additional, Hegele, Robert A, additional, Al-Rasadi, Khalid, additional, Arca, Marcello, additional, Averna, Maurizio, additional, Bruckert, Eric, additional, Freiberger, Tomas, additional, Gaudet, Daniel, additional, Harada-Shiba, Mariko, additional, Hudgins, Lisa C, additional, Kayikcioglu, Meral, additional, Masana, Luis, additional, Parhofer, Klaus G, additional, Roeters van Lennep, Jeanine E, additional, Santos, Raul D, additional, Stroes, Erik S G, additional, Watts, Gerald F, additional, Wiegman, Albert, additional, Stock, Jane K, additional, Tokgözoğlu, Lale S, additional, Catapano, Alberico L, additional, and Ray, Kausik K, additional
- Published
- 2023
- Full Text
- View/download PDF
41. From the EAS:* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
- Author
-
Kronenberg, Florian, primary, Mora, Samia, additional, Stroes, Erik S.G., additional, Ference, Brian A., additional, Arsenault, Benoit J., additional, Berglund, Lars, additional, Dweck, Marc R., additional, Koschinsky, Marlys L., additional, Lambert, Gilles, additional, Mach, François, additional, McNeal, Catherine J., additional, Moriarty, Patrick M., additional, Natarajan, Pradeep, additional, Nordestgaard, Børge G., additional, Parhofer, Klaus G., additional, Virani, Salim S., additional, von Eckardstein, Arnold, additional, Watts, Gerald F., additional, Stock, Jane K., additional, Ray, Kausik K., additional, Tokgözoğlu, Lale S., additional, and Catapano, Alberico L., additional
- Published
- 2023
- Full Text
- View/download PDF
42. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
- Author
-
Kronenberg, Florian; https://orcid.org/0000-0003-2229-1120, Mora, Samia; https://orcid.org/0000-0001-6283-0980, Stroes, Erik S G; https://orcid.org/0000-0001-9555-6260, Ference, Brian A, Arsenault, Benoit J; https://orcid.org/0000-0003-2240-8456, Berglund, Lars, Dweck, Marc R; https://orcid.org/0000-0001-9847-5917, Koschinsky, Marlys L, Lambert, Gilles; https://orcid.org/0000-0001-5632-0685, Mach, François; https://orcid.org/0000-0003-3178-9131, McNeal, Catherine J; https://orcid.org/0000-0003-0655-2052, Moriarty, Patrick M, Natarajan, Pradeep; https://orcid.org/0000-0001-8402-7435, Nordestgaard, Børge G; https://orcid.org/0000-0002-1954-7220, Parhofer, Klaus G; https://orcid.org/0000-0001-9873-0412, Virani, Salim S; https://orcid.org/0000-0001-9541-6954, von Eckardstein, Arnold; https://orcid.org/0000-0002-1666-2266, Watts, Gerald F, Stock, Jane K, Ray, Kausik K, Tokgözoğlu, Lale S, Catapano, Alberico L; https://orcid.org/0000-0002-7593-2094, Kronenberg, Florian; https://orcid.org/0000-0003-2229-1120, Mora, Samia; https://orcid.org/0000-0001-6283-0980, Stroes, Erik S G; https://orcid.org/0000-0001-9555-6260, Ference, Brian A, Arsenault, Benoit J; https://orcid.org/0000-0003-2240-8456, Berglund, Lars, Dweck, Marc R; https://orcid.org/0000-0001-9847-5917, Koschinsky, Marlys L, Lambert, Gilles; https://orcid.org/0000-0001-5632-0685, Mach, François; https://orcid.org/0000-0003-3178-9131, McNeal, Catherine J; https://orcid.org/0000-0003-0655-2052, Moriarty, Patrick M, Natarajan, Pradeep; https://orcid.org/0000-0001-8402-7435, Nordestgaard, Børge G; https://orcid.org/0000-0002-1954-7220, Parhofer, Klaus G; https://orcid.org/0000-0001-9873-0412, Virani, Salim S; https://orcid.org/0000-0001-9541-6954, von Eckardstein, Arnold; https://orcid.org/0000-0002-1666-2266, Watts, Gerald F, Stock, Jane K, Ray, Kausik K, Tokgözoğlu, Lale S, and Catapano, Alberico L; https://orcid.org/0000-0002-7593-2094
- Published
- 2023
43. Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice
- Author
-
Catapano, Alberico L., Lautsch, Dominik, Tokgözoglu, Lale, Ferrieres, Jean, Horack, Martin, Farnier, Michel, Toth, Peter P., Brudi, Philippe, Tomassini, Joanne E., Ambegaonkar, Baishali, and Gitt, Anselm K.
- Published
- 2016
- Full Text
- View/download PDF
44. The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology
- Author
-
De Smedt, Delphine, De Bacquer, Dirk, De Sutter, Johan, Dallongeville, Jean, Gevaert, Sofie, De Backer, Guy, Bruthans, Jan, Kotseva, Kornelia, Reiner, Željko, Tokgözoğlu, Lale, and Clays, Els
- Published
- 2016
- Full Text
- View/download PDF
45. Atherosclerosis
- Author
-
Libby, Peter, Buring, Julie E., Badimon, Lina, Hansson, Göran K., Deanfield, John, Bittencourt, Márcio Sommer, Tokgözoğlu, Lale, and Lewis, Eldrin F.
- Published
- 2019
- Full Text
- View/download PDF
46. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
- Author
-
Fruchart, Jean-Charles, Santos, Raul D., Aguilar-Salinas, Carlos, Aikawa, Masanori, Al Rasadi, Khalid, Amarenco, Pierre, Barter, Philip J., Ceska, Richard, Corsini, Alberto, Després, Jean-Pierre, Duriez, Patrick, Eckel, Robert H., Ezhov, Marat V., Farnier, Michel, Ginsberg, Henry N., Hermans, Michel P., Ishibashi, Shun, Karpe, Fredrik, Kodama, Tatsuhiko, Koenig, Wolfgang, Krempf, Michel, Lim, Soo, Lorenzatti, Alberto J., McPherson, Ruth, Nuñez-Cortes, Jesus Millan, Nordestgaard, Børge G., Ogawa, Hisao, Packard, Chris J., Plutzky, Jorge, Ponte-Negretti, Carlos I., Pradhan, Aruna, Ray, Kausik K., Reiner, Željko, Ridker, Paul M., Ruscica, Massimiliano, Sadikot, Shaukat, Shimano, Hitoshi, Sritara, Piyamitr, Stock, Jane K., Su, Ta-Chen, Susekov, Andrey V., Tartar, André, Taskinen, Marja-Riitta, Tenenbaum, Alexander, Tokgözoğlu, Lale S., Tomlinson, Brian, Tybjærg-Hansen, Anne, Valensi, Paul, Vrablík, Michal, Wahli, Walter, Watts, Gerald F., Yamashita, Shizuya, Yokote, Koutaro, Zambon, Alberto, and Libby, Peter
- Published
- 2019
- Full Text
- View/download PDF
47. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society.
- Author
-
Lennep, Jeanine E Roeters van, Tokgözoğlu, Lale S, Badimon, Lina, Dumanski, Sandra M, Gulati, Martha, Hess, Connie N, Holven, Kirsten B, Kavousi, Maryam, Kayıkçıoğlu, Meral, Lutgens, Esther, Michos, Erin D, Prescott, Eva, Stock, Jane K, Tybjaerg-Hansen, Anne, Wermer, Marieke J H, and Benn, Marianne
- Subjects
PREMATURE menopause ,CARDIOVASCULAR diseases ,POLYCYSTIC ovary syndrome ,CARDIOVASCULAR diseases risk factors ,MIDDLE-aged women ,ATHEROSCLEROSIS - Abstract
Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good evidence that these are associated with greater cardiovascular risk. This position statement from the European Atherosclerosis Society focuses on these factors, as well as sex-specific effects on lipids, including lipoprotein(a), over the life course in women which impact ASCVD risk. Women are also disproportionately impacted (in relative terms) by diabetes, chronic kidney disease, and auto-immune inflammatory disease. All these effects are compounded by sociocultural components related to gender. This panel stresses the need to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network
- Author
-
Catapano, Alberico L, Tokgözoğlu, Lale, Banach, Maciej, Gazzotti, Marta, Olmastroni, Elena, Casula, Manuela, Ray, Kausik K, the Lipid Clinics Network, Alaa ABDELRAZIK (University Hospital of North Midland, United Kingdom), Alberto MELLO E SILVA (Sociedade Portuguesa de Aterosclerose, Portugal), Alexander VONBANK (VIVIT Institute, Austria), Alexandros, D TSELEPIS (Dept of Chemistry, Atherothrombosis Research Center, University of Ioannina, Greece), Alper SONMEZ (Department of Endocrinology and Metabolism, Ankara Guven Hospital, Turkey), Angelina PASSARO (Department of Translational Medicine, University of Ferrara &, Center for the Study and Treatment of Metabolic Diseases, Atherosclerosis, and Clinical Nutrition, University Hospital of Ferrara Arcispedale Sant’Anna, Italy), Anja VOGT (Medizinische Klinik und Poliklinik IV, Klinikum der Universit¨at München, Germany), Ann MERTENS (Clinical and Experimental Endocrinology, Leuven, Ku, Leuven, Belgium), Ann VERHAEGEN (Antwerp University Hospital, Belgium), Arman, S POSTADZHIYAN (Medical University of Sofia, Saint Anna University Hospital, Departement of Cardiology, Bulgaria), BAHADIR KIRILMAZ (Canakkale Onsekiz Mart University, Medical Faculty Cardiology Dept, Baris GUNGOR (University of Health Sciences Dr. Siyami Ersek Hospital, Turkey), Berit S HEDEGAARD (Aalborg University, Denmark), Bertrand CARIOU (Nantes Universit´e, Chu, Nantes, Cnrs, Inserm, l’institut du thorax, Nantes, France), Britta OTTE (Universit¨atsklinikum Münster, Lipidambulanz, Germany), Bu˘gra ¨OZKAN (Mersin University, Turkey), of cardiology, Christ BERGE (Dept., Unversity Hopsital, Haukeland., Norway), F EBENBICHLER (Department for Internal Medicine I, Christoph, Medical University Innsbruck, Austria), Christoph J BINDER (Medical University of Vienna, Austria), Christoph OLIVIER (Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Conrad AZZOPARDI (Mater Dei Hospital, Malta), Cristina SOLER (Lipid Unit, Hospital de Sta Caterina, Spain), Dan GAITA (Universitatea de Medicina si Farmacie Victor Babes din Timisoara &, Clinica de Cardiologie, Institutul de Boli Cardiovasculare Timisoara, Romania), Daniel WEGHUBER (Department of Pediatrics, Paracelsus Medical University, Dilek URAL (Koç University School of Medicine Department of Cardiology, Turkey), Diogo CRUZ (Hospital de Cascais - Dr. Jos´e de Almeida, Portugal), Dragos VINEREANU (University of Medicine and Pharmacy, University and Emergency Hospital, Bucharest, Romania), Elena D PENCU (Grand Hˆopital de Charleroi GHDC, Belgium), Emil HAGSTR¨OM (Dept of medical sciences, Uppsala, University, Sweden), Erik B SCHMIDT (Aalborg University, Denmark), Erik, S STROES (Dept of vascular medicine, Amsterdamumc, The, Netherlands), Evangelos LIBEROPOULOS (1st Department of Propedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, Fabian DEMEURE (CHU UCL Namur - Site Godinne, Belgium), Fabio FIMIANI (Azienda Ospedaliera di Rilievo Nazionale AORN Dei Colli, Monaldi', 'V., Unit of Inherited and Rare Cardiovascular Diseases, Italy, ), Fabio PELLEGATTA (Center for the Study of Atherosclerosis. Bassini Hospital. Cinisello Balsamo, Italy), Fahri BAYRAM (Erciyes University, Turkey), Finn L HENRIKSEN (Department of Cardiology Odense University Hospital, Denmark), Florian H¨OLLERL (1st Medical Department, Landstrasse, Clinic, Vienna Health Association, Francesco CIPOLLONE (Clinica Medica Institute of, Department of Medicine and Aging Sciences, d’Annunzio' University, 'G., Francisco ARAÚJO (Hospital Lusíadas, Portugal), Franck BOCCARA (Sorbonne Universit´e, Groupe de Recherche Clinique number 22, C2MV—Complications Cardiovasculaires et M´etaboliques chez les Patients Vivant avec le Virus de l’Immunod´eficience Humaine, Institut National de la Sant´e et de la Recherche M´edicale Unit´e Mixte de Recherche, S 938, Centre de Recherche Saint-Antoine, Institut Hospital Universitaire de Cardiom ´etabolisme et Nutrition Cardiologie, Hˆopital Saint Antoine Assistance Publique–Hˆopitaux de Paris, Paris, France), François PAILLARD (Cardiologie et Centre Clinico-Biologique des Lipides et Ath´eroscl´erose, Chu, Rennes, France), Imre University Teaching Hospital, Gabor SIMONYI (DBC St., Metabolic, Center, Lipid, Center, Hungary), Gabriella IANNUZZO (Department of Clinical Medicine and Surgery. University of Naples Federico II, Italy), Giuseppe MANDRAFFINO (Department of Clinical and Experimental Medicine, - Lipid Center, University of Messina, Graham BAYLY (Dept Clinical Biochemistry, University Hospitals Bristol, United, Kingdom), Gustavs LATKOVSKIS (Institute of Cardiology and Regenerative Medicine, University of Latvia &, Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital &, University of Latvia, Latvia), Gy¨orgy PARAGH (Division of Metabolic Disorders, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary), Hana ROSOLOVA (Charles University Prague Medical Hospital in Pilsen, Czech Republic), Handrean SORAN (Central Manchester University Hospital NHS Foundation Trust, United Kingdom), Helle KANSTRUP (Department of cardiology, Aarhus University hospital, Denmark), Hermann TOPLAK (Department of Medicine, Division of Endocrinology and Diabetology, Medical University Graz, Hülya ÇIÇEKÇIO ˘GLU (ankara bilkent city hospital, Turkey), Inanc ARTAC (Department of Cardiology, Kafkas University Hospital, Ioanna GOUNI-BERTHOLD (Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Irfan, V DUZEN (Gaziantep University, Cardiology, Department, Isabel M PALMA (CHUPORTO - Centro Hospitalar Universit ´ario do Porto, Portugal), Istvan REIBER (Szent Gyorgy University Teaching Hospital of Fejer County, Hungary), Iveta DZIVITE-KRISANE (Children’s University Hospital, Latvia), Jeanine, E ROETERS VAN LENNEP (Department of Internal medicine, Erasmus MC University Medical Center, Jean-Luc, J BALLIGAND (Institut de Recherche Exp´erimentale et Clinique, Universite catholique de Louvain, Bruxelles), Joao C PORTO (CHUC, Portugal), Jo˜ao, S DUARTE (Hospital Egas Moniz, Lisboa, Portugal), Johan DE SUTTER (AZ Maria Middelares Hospital Gent, Belgium), Jos´e L´OPEZ-MIRANDA (Lipid and Arteriosclerosis Unit. Department of Internal Medicine. Hospital Universitario Reina Sofia. IMIBIC. University of Cordoba. CiberOBN, Spain), Jose M MOSTAZA (Hospital La Paz-Carlos III, Spain), Jurgita PLISIENE (Lithuanian University of Health sciences, Lithuania), Kadir, U MERT (Eskis ¸ehir Osmangazi University, Department of Cardiology, Kirsten, B HOLVEN (Department of Nutrition, University of Oslo and National Advisory unit on FH, Oslo University Hospital, Kjetil RETTERSTØL (The Lipid Clinic, Oslo University Hospital and Department of Nutrition, University of Oslo, Kristian, K THOMSEN (University Hospital of South Denmark, Esbjerg, Denmark), Lale TOKGOZOGLU (Hacettepe University, Turkey), Laszlo BAJNOK (1st Department of Medicine, Medical, School, University of Pecs, Lia E BANG (Copenhagen University Hospital, Denmark), Liliana GRIGORE (IRCCS Multimedica, Italy), Lluís MASANA (Hospital Universitari Sant Joan. Universitat Rovira i Virgili. CIBERDEM. Reus, Spain), Loukianos S RALLIDIS (University General Hospital Attikon, Greece), Maciej BANACH (Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Poland), Małgorzata WALU´S-MIARKA (Jagiellonian University Medical College, Of Metabolic Diseases and Diabetology, Dept., Manuel CASTRO CABEZAS (Franciscus Gasthuis &, Vlietland Rotterdam, The Netherlands), Marcello ARCA (Sapienza University of Rome, Italy), Margus VIIGIMAA (North Estonia Medical Centre, Tallinn University of Technology, Estonia), Martin, P BOGSRUD (Unit for Cardiac and Cardiovascular Genetics, Matej MLINARIˇC (Department of Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, Slovenia), Matteo PIRRO (Section of Internal Medicine, Angiology and Arteriosclerosis Diseases, Maurizio AVERNA (Department PROMISE-University of Palermo &, Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Palermo, Italy), Meral KAYIKCIOGLU (Ege University Medical School Department of Cardiology, Turkey), Merete HEITMANN (Bispebjerg-Frederiksberg University Hospital, Denmark), Mette MOURIDSEN (Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Michal VRABLIK (3rd Department of Internal Medicine, General University Hospital and 1st Medical Faculty, Charles, University, Prague, Czech, Republic), Michel FARNIER (PEC2, University of Bourgogne Franche-Comt´e, Laboratory Medicine, Michel R LANGLOIS (Dept., Jan Hospital, AZ St., Belgium), Milad KHEDR (Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Muge ILDIZLI DEMIRBAS (Kartal Kosuyolu Research and Training Hospital, Turkey), Myra TILNEY (Lipid Clinic, Mater Dei Hospital &, Dept of Medicine, University of Malta Medical School, Malta), Nadia CITRONI (Internal Medicine, APSS Trento Hospital, Of Internal Medicine, Niels P RIKSEN (Dept., Radboud university medical center, Nikolay M RUNEV (UMHAT Alexandrovska, Bulgaria), Nora KUPSTYTEKRISTAPONE (Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Lithuania), Olena MITCHENKO (NSC, Clinical and Regenerative Medicine of the NAMS of Ukraine, Ukraine), Oliver WEING¨ARTNER (Universit¨atsklinikum Jena, Department of Internal Medicine, I, Oner OZDOGAN (University of Health Sciences, Izmir Faculty of Medicine, Tepecik Training and Research Hospital, Ovidio MU˜NIZGRIJALVO (Hospital Virgen del Rocío, Spain), Ozcan BASARAN (Mugla Sitki Kocman University, Pankaj GUPTA (University Hospitals of Leicester, United Kingdom), Paolo PARINI (Cardio Metabolic Unit, Karolinska, Institutet, and Theme Inflammation and Ageing, Karolinska University Hospital Huddinge, Patrizia SUPPRESSA (Department of Internal Medicine and rare disease Centre, Bari, Italy), Paul DOWNIE (Salisbury NHS Foundation trust, United Kingdom), Pavel JESINA (Metabolic Center General University Hospital, Czech Republic), of Internal Medicine, Pavel KRAML (Dept., Third Faculty of Medicine, Charles University and Kr´alovsk´e Vinohrady University Hospital Prague, Pawel BURCHARDT (Department of Cardiology, Cardiovascular, Unit, Hospital, J. Stru´s., Pozna´n, &, Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences, Pozna´n, Poland), Pedro VALDIVIELSO (Hospital VIRGEN DE LA VICTORIA, Spain), Pedro VON HAFE (Instituto Cuf, Portugal), Dept, Peter FASCHING (5th Med., Clinic, Ottakring, Philippe MOULIN (Hospices civils de Lyon/INSERM/Universit ´e Lyon1, Hˆopital Louis Pradel, F´ed´eration, D’Endocrinologie, Quit´eria RATO (Sociedade Portuguesa de Aterosclerose, Portugal), Reinhold INNERHOFER (Medical University Vienna, Austria), Renata C´IFKOV´A (Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer University Hospital, Rene VALERO (Aix Marseille Univ, Aphm, Inserm, Inrae, C2vn, University Hospital La Conception, Department of Nutrition, Metabolic Diseases and Endocrinology, Scicali, Roberto, Robin URB´ANEK (Internal medicine, Obezita-Ormiga, s. r. o., Roma KAVALIAUSKIENE (Klaip˙ eda Seamen’s Hospital, Lituania), Roman CIBULKA (Department of paramedic science, medical diagnostics studies and public health, Faculty of Health Care Studies, University of West Bohemia, Sabina ZAMBON (Department of Medicine, - DIMED, University of Padova, Sergio D’ADDATO (University of Bologna. IRCCS S. Orsola Bologna, Italy), Stanislav ZEMEK (Lipidova ambulance, Czech Republic), Stefano ROMEO (Gothenburg University, Sweden), Stephanie K¨ONEMANN (Department of Internal Medicine, B, University Medicine Greifswald, DZHK (German Centre for Cardiovascular Research), Susanne GREBER-PLATZER (Clinical Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Thomas STULNIG (Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University Vienna &, Third Medical Department and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic, Hietzing, Vienna, Austria), Thomas MUHR (Dept of Cardiology, Link¨oping University Hospital, Tina, Z KHAN (Consultant Cardiologist, Royal Brompton and Harefield Hospitals Part of Guy’s and St Thomas’ NHS Foundation Trust, Tomas FREIBERGER (Centre of Cardiovascular Surgery and Transplantation, Brno &, Medical, Faculty, Masaryk, University, Brno, Tom´aˇs ˇS´ALEK (Metabolic Clinic, Tomas Bata Hospital, Zlín, Tomas VASYLIUS (Republican Panevezys hospital, Of Cardiology, Dep., Lithuania), Ulrich LAUFS (Klinik und Poliklinik für Kardiologie, Universit ¨atsklinikum Leipzig, Ulrike SCHATZ (University Hospital Carl Gustav Carus Dresden at the Technical University Dresden, Department of Internal Medicine III, Urh GROSELJ (UMC, - University Children’s Hospital Ljubljana, University of Ljubljana, Victoria MARCO-BENEDI (Hospital Universitario Miguel Servet, Iisa, Cibercv, Vincent MAHER (Advanced Lipid Management and Research ALMAR centre, Tallaght University Hospital, Ireland), Vladimír BLAHA (University Hospital Hradec Kr´alov´e and Charles University, Faculty of Medicine in Hradec Kr´alov´e, 3rd Department of Internal Medicine, - Metabolism and Gerontology, Vladimir SOSKA (Department of Clinical Biochemistry, St. Anne’s University Hospital Brno, 2nd Clinic of Internal Medicine, Masaryk University Brno, Volker JJ SCHETTLER (Centre of Nephrology G¨ottingen, Germany), Wolfgang REINHARDT (SUS Malmoe, Sweden), Xavier PINT´O (Hospital Universitari de Bellvitge-Idibell-UB-CiberObn, Spain), Yoto YOTOV (Second Cardiology Clinic, Marina, University Hospital Sv., Medical University of Varna, Zaneta PETRULIONIENE (Vilnius University Medical Faculty, Vilnius University Hospital Santaros klinikos, Lithuania), ˇZeljko REINER (Department for Metabolic Diseases, University Hospital Center Zagreb, and Croatia, ).
- Subjects
Clinicians ,Clinical evaluation ,Cardiology and Cardiovascular Medicine ,Cardiovascular risk ,Lipoprotein(a) - Published
- 2023
49. Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach
- Author
-
Yılmaz, MEHMET BİRHAN, Aydoğdu, Sinan, Özer, Necla, Abacı, Adnan, Kılıçkap, Mustafa, Kayıkçıoğlu, Meral, Kızılırmak, Pınar, Öngen, Zeki, Güleç, Sadi, Tokgözoğlu, Lale, Dölek, Bilgen, Bozkurt, Engin, and Temizhan, Ahmet
- Abstract
Objective: The aim of this study is to analyze the low-density lipoprotein cholesterol-lowering therapies in secondary prevention patients by anatyzing their plasma low-density lipoprotein cholesterol levels. current treatment, considering their inadequate response to medications (as defined in current guidelines), and the requirement for a protein convertase subtilisin/kexin type 9 inhibitor. Methods: Delphi panel is used to seek expert consensus of experienced 12 cardiologists. A questionnaire consisting of 6 main questions is used to reflect the opinion of the expert panetists on the practices of tow-density lipoprotein cholesterol-lowering therapies of patients with high and very high cardiovascular risk. Patients with atheroscterotic cardiovascutar disease are covered in this present analysis. Results: According to expert opinion data. 18.6% of the patient population with atherosclerotic cardiovascular disease is estimated to have experienced recurrent vascular events. The current treatment of the patient population is 39.7% on high dose. 36.9% on tow/moderate dose of statin, 13.1% on maximum tolerated dose statin + ezetimibe, and 1.2% on maximum tolerated dose statin + ezetimibe + protein convertase subtilisin/kexin type 9 inhibitor. The percentage of atherosclerotic cardiovascular disease patients with inadequate treatment response is estimated to be 20.2% in those using "maximum tolerated dose statin + ezetimibe." The proportion of patients who wilt need to be treated with a protein convertase subtilisin/kexin type 9 inhibitor increases as their low-density lipoprotein cholesterol levels rises from 9.1% in 70-99 mg/dL to 50.8% in >= 160 mg/dL for these patients. Conclusion: According to expert opinion, although a substantial proportion of patients with secondary prevention have not achieved tow-density lipoprotein cholesterol goals, the use of protein convertase subtilisin/kexin type 9 inhibitors is very tow. Since the questionnaire subject to panel discussion did not include any question elaborating the issue. the discrepancy between the recommendation of the related guidelines and Turkish practice needs further studies for the explanation.
- Published
- 2022
50. In memoriam: Akira Endo.
- Author
-
Catapano, Alberico L, Pirillo, Angela, and Tokgözoğlu, Lale
- Subjects
BLOOD cholesterol ,MICROBIOLOGY ,DIETARY patterns ,MOLDS (Fungi) ,OLDER people - Abstract
Dr. Akira Endo, a Japanese scientist, made significant contributions to cardiovascular medicine through his discovery of statins. Born in 1933, Dr. Endo's fascination with fungi and molds led him to study biochemistry and eventually join Sankyo Co. in Tokyo as a research scientist. While in the United States during the 1960s, he became interested in cholesterol biosynthesis and dedicated years of research to finding natural products that could inhibit this process. In 1972, he discovered a mold that strongly inhibited cholesterol synthesis, leading to the identification of citrinin. However, due to its toxicity, the research was discontinued. Undeterred, Dr. Endo continued his work and in 1976, he published the discovery of compactin, the first statin. Despite initial setbacks, his perseverance and resilience led to the development of lovastatin, which became available in 1987. Dr. Endo's contributions to cardiovascular medicine have had a profound impact on public health by reducing the risk of heart attacks and strokes. He received numerous awards for his work, including the Lasker Award in 2008 and the Gairdner Prize in 2017. Dr. Endo passed away in 2024 at the age of 90, leaving behind a legacy as a great scientist who saved millions of lives. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.